Skip to main content
. 2022 Apr 5;14:1341–1352. doi: 10.2147/CMAR.S348529

Figure 1.

Figure 1

Flow chart showing an overview of the study. Patients with breast, melanoma, pancreatic, prostate or ovarian tumors tested for BRCA1 and BRCA2 gene mutation.

Abbreviations: PVs, pathogenic variants; VUS, variants of uncertain significance; WT, wild-type BRCA1/2 sequence.